GoingToMeet

There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients. The industry faces a sustained increase in the cost of healthcare and ever-increasing range of expensive drugs and technologies available as potential therapies.

Many examples of complex agreements exist in practice, whilst many governments and pharma companies have far less experience with such schemes. All stakeholders need answers to important questions such as: “What is the definition of risk-sharing and value-based pricing schemes? Are such schemes necessary? What are the alternatives? What successful models exist? How can clear endpoints and goals be defined? How can we measure performance effectively? How different schemes are being viewed by different stakeholders? Can risk-sharing and value-based agreements bring a competitive advantage to pharma companies?”

Why Attend?

Understand the opportunities, obstacles and challenges in designing and implementing innovative agreements.

Find out when risk-sharing & value-based agreements are required and how they can be designed to satisfy all stakeholders to gain market access.

Understand whether or not the turbulent macroeconomic environment will increase payer motivation for flexible agreements.

Obtain the best and most focused picture of risk-sharing and value-based pricing models today.

Learn how drug effectiveness is being demonstrated in different regions.

Understand the best ways to communicate value and achieve maximum patient and market access.

Hear the perspectives of all stakeholder groups: Payers, regulators, insurers, health economists and the pharmaceutical industry.

Discover how payers are evaluating conditional reimbursement agreements.